Cargando…
Better influenza vaccines: an industry perspective
Vaccination is the most effective measure at preventing influenza virus infections. However, current seasonal influenza vaccines are only protective against closely matched circulating strains. Even with extensive monitoring and annual reformulation our efforts remain one step behind the rapidly evo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023813/ https://www.ncbi.nlm.nih.gov/pubmed/32059697 http://dx.doi.org/10.1186/s12929-020-0626-6 |
_version_ | 1783498333720936448 |
---|---|
author | Chen, Juine-Ruey Liu, Yo-Min Tseng, Yung-Chieh Ma, Che |
author_facet | Chen, Juine-Ruey Liu, Yo-Min Tseng, Yung-Chieh Ma, Che |
author_sort | Chen, Juine-Ruey |
collection | PubMed |
description | Vaccination is the most effective measure at preventing influenza virus infections. However, current seasonal influenza vaccines are only protective against closely matched circulating strains. Even with extensive monitoring and annual reformulation our efforts remain one step behind the rapidly evolving virus, often resulting in mismatches and low vaccine effectiveness. Fortunately, many next-generation influenza vaccines are currently in development, utilizing an array of innovative techniques to shorten production time and increase the breadth of protection. This review summarizes the production methods of current vaccines, recent advances that have been made in influenza vaccine research, and highlights potential challenges that are yet to be overcome. Special emphasis is put on the potential role of glycoengineering in influenza vaccine development, and the advantages of removing the glycan shield on influenza surface antigens to increase vaccine immunogenicity. The potential for future development of these novel influenza vaccine candidates is discussed from an industry perspective. |
format | Online Article Text |
id | pubmed-7023813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70238132020-02-20 Better influenza vaccines: an industry perspective Chen, Juine-Ruey Liu, Yo-Min Tseng, Yung-Chieh Ma, Che J Biomed Sci Review Vaccination is the most effective measure at preventing influenza virus infections. However, current seasonal influenza vaccines are only protective against closely matched circulating strains. Even with extensive monitoring and annual reformulation our efforts remain one step behind the rapidly evolving virus, often resulting in mismatches and low vaccine effectiveness. Fortunately, many next-generation influenza vaccines are currently in development, utilizing an array of innovative techniques to shorten production time and increase the breadth of protection. This review summarizes the production methods of current vaccines, recent advances that have been made in influenza vaccine research, and highlights potential challenges that are yet to be overcome. Special emphasis is put on the potential role of glycoengineering in influenza vaccine development, and the advantages of removing the glycan shield on influenza surface antigens to increase vaccine immunogenicity. The potential for future development of these novel influenza vaccine candidates is discussed from an industry perspective. BioMed Central 2020-02-14 /pmc/articles/PMC7023813/ /pubmed/32059697 http://dx.doi.org/10.1186/s12929-020-0626-6 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Chen, Juine-Ruey Liu, Yo-Min Tseng, Yung-Chieh Ma, Che Better influenza vaccines: an industry perspective |
title | Better influenza vaccines: an industry perspective |
title_full | Better influenza vaccines: an industry perspective |
title_fullStr | Better influenza vaccines: an industry perspective |
title_full_unstemmed | Better influenza vaccines: an industry perspective |
title_short | Better influenza vaccines: an industry perspective |
title_sort | better influenza vaccines: an industry perspective |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023813/ https://www.ncbi.nlm.nih.gov/pubmed/32059697 http://dx.doi.org/10.1186/s12929-020-0626-6 |
work_keys_str_mv | AT chenjuineruey betterinfluenzavaccinesanindustryperspective AT liuyomin betterinfluenzavaccinesanindustryperspective AT tsengyungchieh betterinfluenzavaccinesanindustryperspective AT mache betterinfluenzavaccinesanindustryperspective |